Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
ProPhase Labs's operating assets for the quarter that ended in Dec. 2025 was $59.78 Mil. ProPhase Labs's operating liabilities for the quarter that ended in Dec. 2025 was $47.75 Mil. ProPhase Labs's Total Assets for the quarter that ended in Sep. 2025 was $65.70 Mil. Therefore, ProPhase Labs's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.18.
ProPhase Labs Scaled Net Operating Assets Related Terms
ProPhase Labs Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs NSTM, IDTA, IVRO: Scaled Net Operating Assets Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Scaled Net Operating Assets vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.18 mean?
ProPhase Labs (PRPH) has a Scaled Net Operating Assets of 0.18 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on ProPhase Labs and its competitors.
Is ProPhase Labs' Scaled Net Operating Assets too high?
ProPhase Labs' current Scaled Net Operating Assets is 0.18.
How does ProPhase Labs' Scaled Net Operating Assets compare to NSTM and IDTA?
ProPhase Labs' Scaled Net Operating Assets of 0.18 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Diagnostics & Research company?
A good Scaled Net Operating Assets depends on the Medical Diagnostics & Research industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on ProPhase Labs and its competitors. ProPhase Labs's current Scaled Net Operating Assets is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current Scaled Net Operating Assets is 0.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Scaled Net Operating Assets is 0.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 